American Society of Hematology Annual Meeting

Survival Outcomes Not Improved With Autologous Stem Cell Transplant in MCL

December 11th 2024, 1:11am

Article

Autologous stem cell transplant plus Rituxan did not improve survival outcomes in certain patients with mantle cell lymphoma compared with Rituxan alone.

Blenrep Combo Improves Survival in Relapsed/Refractory Multiple Myeloma

December 10th 2024, 8:48pm

Article

Updated data from the phase 3 DREAMM-7 trial was presented during the 2024 ASH Annual Meeting and Exposition.

Uproleselan Fails to Improve Survival in AML, Although Some Subgroups May Benefit

December 10th 2024, 4:00pm

Article

A Phase 3 trial of uproleselan failed to improve overall survival in relapsed/refractory AML, though it may benefit primary refractory patients.

Venclexta Plus Mavenclad Boosts Response Rates in AML, MDS

December 10th 2024, 2:05pm

Article

The Venclexta-based regimen improved complete response rates in patients with acute myeloid leukemia and myelodysplastic syndromes.

Heart Risk May Occur Less With Some BTK Inhibitors in B-Cell Blood Cancers

December 9th 2024, 11:00pm

Article

In patients with certain B-cell blood cancers, heart-related side effects may occur less after receiving second-generation BTK inhibitors.

Brukinsa Supported as First-Line Treatment for Patients With CLL/SLL

December 9th 2024, 10:00pm

Article

Patients with treatment-naive CLL/SLL experienced long-term improved efficacy when treated with Brukinsa compared with bendamustine plus Rituxan.

Pelabresib Plus Jakafi Maintains Efficacy in JAK-Naive Myelofibrosis

December 9th 2024, 9:17pm

Article

Adding pelabresib to a JAK inhibitor may improve multiple aspects of myelofibrosis, including spleen size, symptoms and bone marrow fibrosis.

Tecvayli Effective Maintenance Therapy in Newly Diagnosed Multiple Myeloma

December 9th 2024, 5:00pm

Article

Tecvayli alone or plus Revlimid has been found to be safe and may result in high MRD-negativity rates.

Darzalex Faspro May Improve Progression, Survival in Smoldering Multiple Myeloma

December 9th 2024, 3:00pm

Article

The risk for disease progression or death was reduced by 51% with subcutaneous Darzalex Faspro in certain patients with smoldering multiple myeloma.

Calquence Plus Venclexta Combo May Improve Survival in Frontline CLL

December 9th 2024, 12:50am

Article

Calquence plus Venclexta, with or without Gazyva, improved progression-free survival over the standard-of-care chemoimmunotherapy in patients with untreated chronic lymphocytic leukemia.